Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infections

Journal of Immunology

Volumn 189, Issue 10, 2012, Pages 4921-4929

  Haynes, Laura ^a   Szaba, Frank M ^a   Eaton, Sheri M ^a   Kummer, Lawrence W ^a   Lanthier, Paula A ^a   Petell, Ashlee H ^a   Duso, Debra K ^a   Luo, Deyan ^a,b   Lin, Jr Shiuan ^a   Lefebvre, Julie S ^a   Randall, Troy D ^a,c   Johnson, Lawrence L ^a   Kohlmeier, Jacob E ^a,d   Woodland, David L ^a,e   Smiley, Stephen T ^a  

^a TRUDEAU INSTITUTE   (United States)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c and Clinical Center   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Keystone Symposia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; COLONY FORMING UNIT; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; SECONDARY INFECTION; SENDAI VIRUS INFECTION; STREPTOCOCCUS PNEUMONIAE; T CELL DEPLETION; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; DISEASE SUSCEPTIBILITY; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; NUCLEOCAPSID PROTEINS; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; T-LYMPHOCYTES;

EID: 84868516224     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201916     Document Type: Article

References (53)

1. McCullers, J. A. 2006. Insights into the interaction between influenza virus and pneumococcus. Clin. Microbiol. Rev. 19: 571-582.
2. Stöhr, K. 2003. Preventing and treating influenza. BMJ 326: 1223-1224.
3. Brundage, J. F., and G. D. Shanks. 2008. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg. Infect. Dis. 14: 1193-1199.
4. Rice, T. W., L. Rubinson, T. M. Uyeki, F. L. Vaughn, B. B. John, R. R. Miller, III, E. Higgs, A. G. Randolph, B. E. Smoot, and B. T. Thompson. 2012. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit. Care Med. 40: 1487-1498.
5. Subbarao, K., B. R. Murphy, and A. S. Fauci. 2006. Development of effective vaccines against pandemic influenza. Immunity 24: 5-9.
6. Fiore, A. E., C. B. Bridges, and N. J. Cox. 2009. Seasonal influenza vaccines. Curr. Top. Microbiol. Immunol. 333: 43-82.
7. Grebe, K. M., J. W. Yewdell, and J. R. Bennink. 2008. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 10: 1024-1029.
8. Epstein, S. L., and G. E. Price. 2010. Cross-protective immunity to influenza A viruses. Expert Rev. Vaccines 9: 1325-1341.
9. Slepushkin, A. N. 1959. The effect of a previous attack of A1 influenza on susceptibility to A2 virus during the 1957 outbreak. Bull. World Health Organ. 20: 297-301.
10. Sonoguchi, T., H. Naito, M. Hara, Y. Takeuchi, and H. Fukumi. 1985. Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J. Infect. Dis. 151: 81-88.
11. Nichol, K. L., P. M. Mendelman, K. P. Mallon, L. A. Jackson, G. J. Gorse, R. B. Belshe, W. P. Glezen, and J. Wittes. 1999. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282: 137-144.
12. Epstein, S. L. 2006. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J. Infect. Dis. 193: 49-53.
13. + T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18: 274-280.
14. van der Sluijs, K. F., L. J. van Elden, M. Nijhuis, R. Schuurman, J. M. Pater, S. Florquin, M. Goldman, H. M. Jansen, R. Lutter, and T. van der Poll. 2004. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J. Immunol. 172: 7603-7609.
15. Sun, K., and D. W. Metzger. 2008. Inhibition of pulmonary antibacterial defense by interferon-g during recovery from influenza infection. Nat. Med. 14: 558-564.
16. Shahangian, A., E. K. Chow, X. Tian, J. R. Kang, A. Ghaffari, S. Y. Liu, J. A. Belperio, G. Cheng, and J. C. Deng. 2009. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J. Clin. Invest. 119: 1910-1920.
17. Carragher, D. M., D. A. Kaminski, A. Moquin, L. Hartson, and T. D. Randall. 2008. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 181: 4168-4176.
18. LaMere, M. W., H. T. Lam, A. Moquin, L. Haynes, F. E. Lund, T. D. Randall, and D. A. Kaminski. 2011. Contributions of antinucleoprotein IgG to hetero-subtypic immunity against influenza virus. J. Immunol. 186: 4331-4339.
19. Powell, T. J., T. Strutt, J. Reome, J. A. Hollenbaugh, A. D. Roberts, D. L. Woodland, S. L. Swain, and R. W. Dutton. 2007. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J. Immunol. 178: 1030-1038.
20. + T cell response to respiratory virus infections. Immunity 29: 101-113.
21. Murphy, B. R., R. M. Chanock, M. L. Clements, W. C. Anthony, A. J. Sear, L. A. Cisneros, M. B. Rennels, E. H. Miller, R. E. Black, M. M. Levine, et al. 1981. Evaluation of A/Alaska/6/77 (H3N2) cold-adapted recombinant viruses derived from A/Ann Arbor/6/60 cold-adapted donor virus in adult seronegative volunteers. Infect. Immun. 32: 693-697.
22. Jelley-Gibbs, D. M., J. P. Dibble, D. M. Brown, T. M. Strutt, K. K. McKinstry, and S. L. Swain. 2007. Persistent depots of influenza antigen fail to induce a cytotoxic CD8 T cell response. J. Immunol. 178: 7563-7570.
23. + natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur. J. Immunol. 33: 3322-3330.
24. Lau, H. Y., S. Clegg, and T. A. Moore. 2007. Identification of Klebsiella pneumoniae genes uniquely expressed in a strain virulent using a murine model of bacterial pneumonia. Microb. Pathog. 42: 148-155.
25. Yewdell, J. W., E. Frank, and W. Gerhard. 1981. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J. Immunol. 126: 1814-1819.
26. McCullers, J. A., and J. E. Rehg. 2002. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J. Infect. Dis. 186: 341-350.
27. Armerding, D., H. Rossiter, I. Ghazzouli, and E. Liehl. 1982. Evaluation of live and inactivated influenza A virus vaccines in a mouse model. J. Infect. Dis. 145: 320-330.
28. Tannock, G. A., and J. A. Paul. 1987. Homotypic and heterotypic immunity of influenza A viruses induced by recombinants of the cold-adapted master strain A/Ann Arbor/6/60-ca. Arch. Virol. 92: 121-133.
29. Alymova, I. V., A. Portner, T. Takimoto, K. L. Boyd, Y. S. Babu, and J. A. McCullers. 2005. The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 49: 398-405.
30. Schulman, J. L., and E. D. Kilbourne. 1965. Induction of partial specific het-erotypic immunity in mice by a single infection with influenza A virus. J. Bacteriol. 89: 170-174.
31. Rangel-Moreno, J., D. M. Carragher, R. S. Misra, K. Kusser, L. Hartson, A. Moquin, F. E. Lund, and T. D. Randall. 2008. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J. Immunol. 180: 454-463.
32. Lamere, M. W., A. Moquin, F. E. Lee, R. S. Misra, P. J. Blair, L. Haynes, T. D. Randall, F. E. Lund, and D. A. Kaminski. 2011. Regulation of anti-nucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J. Virol. 85: 5027-5035.
33. Andrew, M. E., B. E. Coupar, G. L. Ada, and D. B. Boyle. 1986. Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants. Microb. Pathog. 1: 443-452.
34. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.
35. Tamura, S., K. Miyata, K. Matsuo, H. Asanuma, H. Takahashi, K. Nakajima, Y. Suzuki, C. Aizawa, and T. Kurata. 1996. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 156: 3892-3900.
36. Epstein, S. L., W. P. Kong, J. A. Misplon, C. Y. Lo, T. M. Tumpey, L. Xu, and G. J. Nabel. 2005. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.
37. Roy, S., G. P. Kobinger, J. Lin, J. Figueredo, R. Calcedo, D. Kobasa, and J. M. Wilson. 2007. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 25: 6845-6851.
38. Price, G. E., M. R. Soboleski, C. Y. Lo, J. A. Misplon, C. Pappas, K. V. Houser, T. M. Tumpey, and S. L. Epstein. 2009. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27: 6512-6521.
39. Casadevall, A., and L. A. Pirofski. 2012. A new synthesis for antibody-mediated immunity. Nat. Immunol. 13: 21-28.
40. Garcia, C. C., R. C. Russo, R. Guabiraba, C. T. Fagundes, R. B. Polidoro, L. P. Tavares, A. P. Salgado, G. D. Cassali, L. P. Sousa, A. V. Machado, and M. M. Teixeira. 2010. Platelet-activating factor receptor plays a role in lung injury and death caused by influenza A in mice. PLoS Pathog. 6: e1001171.
41. Hinojosa, E., A. R. Boyd, and C. J. Orihuela. 2009. Age-associated inflammation and Toll-like receptor dysfunction prime the lungs for pneumococcal pneumonia. J. Infect. Dis. 200: 546-554.
42. Shanks, G. D., and J. F. Brundage. 2012. Pathogenic responses among young adults during the 1918 influenza pandemic. Emerg. Infect. Dis. 18: 201-207.
43. Lanthier, P. A., G. E. Huston, A. Moquin, S. M. Eaton, F. M. Szaba, L. W. Kummer, M. P. Tighe, J. E. Kohlmeier, P. J. Blair, M. Broderick, et al. 2011. Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine 29: 7849-7856.
44. Nimmerjahn, F., and J. V. Ravetch. 2007. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 204: 11-15.
45. Anthony, R. M., T. Kobayashi, F. Wermeling, and J. V. Ravetch. 2011. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475: 110-113.
46. + T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 28: 847-858.
47. Sun, K., J. Ye, D. R. Perez, and D. W. Metzger. 2011. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J. Immunol. 186: 987-993.
48. Ohmit, S. E., J. C. Victor, J. R. Rotthoff, E. R. Teich, R. K. Truscon, L. L. Baum, B. Rangarajan, D. W. Newton, M. L. Boulton, and A. S. Monto. 2006. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 355: 2513-2522.
49. Nichol, K. L., J. D. Nordin, D. B. Nelson, J. P. Mullooly, and E. Hak. 2007. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med. 357: 1373-1381.
50. Garcia-Garcia, L., J. L. Valdespino-Gómez, E. Lazcano-Ponce, A. Jimenez-Corona, A. Higuera-Iglesias, P. Cruz-Hervert, B. Cano-Arellano, A. Garcia-Anaya, E. Ferreira-Guerrero, R. Baez-Saldaña, et al. 2009. Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ 339: b3928.
51. Morens, D. M., J. K. Taubenberger, and A. S. Fauci. 2008. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198: 962-970.
52. Palacios, G., M. Hornig, D. Cisterna, N. Savji, A. V. Bussetti, V. Kapoor, J. Hui, R. Tokarz, T. Briese, E. Baumeister, and W. I. Lipkin. 2009. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS ONE 4: e8540.
53. Centers for Disease Control and Prevention. 2009. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)\United States, May-August 2009. MMWR Morb. Mortal. Wkly. Rep. 58: 1071-1074.